프로티나
Financials
Valuation Metrics
프로티나's Market Cap is ₩5392B. Ranked #423 of 2,405 in KR market (top 18%), #151 of 1,627 on KOSDAQ (top 9%), #47 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 539.15B KRW | KR#423/2,405 Sec#47/231 |
| Revenue | 2.95B KRW | KR#2,357/2,405 Sec#207/231 |
| Net Income | -9.01B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 31.75B KRW | KR#2,317/2,405 Sec#221/231 |
| Net Assets | 28.37B KRW | KR#2,183/2,405 Sec#199/231 |
| Employees | 15 | KR#2,259/2,405 Sec#214/231 |
| Value | ||
| P/B | 19.00x | KR#2,388/2,405 Sec#225/231 |
| P/S | 182.71x | KR#2,386/2,405 Sec#217/231 |
| FCF Yield | -1.70% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -31.76% | KR#2,186/2,405 Sec#178/231 |
| ROA | -28.38% | KR#2,293/2,405 Sec#198/231 |
| Op. Margin | -385.23% | KR#2,339/2,405 Sec#197/231 |
| Financial Health | ||
| Debt Ratio | 11.91% | KR#183/2,405 Sec#35/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | -9.16B KRW | KR#1,672/2,405 Sec#144/231 |
| Cash | 8.79B KRW | KR#1,758/2,405 Sec#156/231 |
| Current Ratio | 15.15x | KR#48/2,405 Sec#16/231 |
| Performance | ||
| 1Y Return | -23.42% | KR#1,443/2,405 Sec#115/231 |
| 1M Return | -5.36% | KR#741/2,405 Sec#73/231 |
| From 52W High | -59.58% | KR#1,643/2,405 Sec#138/231 |
| 1Y MDD | -85.81% | KR#2,357/2,405 Sec#222/231 |
| Trading | ||
| Volume | 188,943 shares | KR#399/2,405 Sec#37/231 |
| Trading Value | 9.28B KRW | KR#210/2,405 Sec#15/231 |
| Foreign Own. | 2.51% | KR#1,447/2,405 Sec#137/231 |
| Per Share | ||
| EPS | -812 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,555 KRW | KR#1,954/2,405 Sec#155/231 |
Company Info
Proteina Co., Ltd. is dedicated to pioneering technology for characterizing protein-protein interactions (PPIs). Their innovative approach enables the direct visualization of specific proteins to confirm the real-time activation of cancer signaling pathways. This capability helps predict drug efficacy and, crucially, empowers medical professionals to select optimal inhibitors by identifying bypass pathways that contribute to drug resistance. The company further offers a distinct single-molecule protein interaction detection platform, designed for in-depth analysis of protein and PPI information. Founded in 2015, Proteina Co., Ltd. is headquartered in Seoul, South Korea.